Literature DB >> 6318673

Uterine adenosarcoma: a clinicopathologic study of 11 cases with a reevaluation of histologic criteria.

B Czernobilsky, P Hohlweg-Majert, G Dallenbach-Hellweg.   

Abstract

Eleven biphasic uterine tumors with epithelial components and homologous stroma were reevaluated. Originally these were diagnosed as adenofibroma, adenosarcoma, carcinosarcoma, or mixtures thereof, but were now reclassified as adenosarcomas of which seven were "pure" and four mixed with foci of carcinosarcoma. Nine of the tumors arose in the endometrium and two in the endocervix. The mean patient's age was 55 years. The most common complaint was vaginal bleeding. Macroscopically these tumors presented as polypoid masses. The epithelial component consisted mainly of endometrial, endocervical, ciliated, and clear cells. Squamous metaplasia and focal hyperplasia were occasionally observed. Malignant epithelial change was only present in foci of carcinosarcoma. The stroma showed prominent cellular periglandular cuffs, occasionally round solid or perivascular nodules, and areas of focal or diffuse stromal hypercellularity. In all these areas stromal cells were atypical and/or pleomorphic. Stromal foam cells were seen in three cases. Mitotic activity was low ranging from one to three mitoses per 10 high power fields (HPF). Follow-up was negative exept in two cases with recurrence and abdominal metastases. It was concluded that stromal hypercellularity with atypism and pleomorphism in periglandular, perivascular location as well as of focal or diffuse nature, is characteristic of uterine adenosarcoma. Adenofibromas present a fibro-collagenous stroma lacking the crowded cellular areas. Mitotic activity is too variable to serve as a reliable diagnostic criterion. Uterine adenosarcomas are usually tumors of low grade malignancy but the lack of correlation between histologic appearance and biologic behaviour precludes prognostication in the individual patient.

Entities:  

Mesh:

Year:  1983        PMID: 6318673     DOI: 10.1007/bf02133803

Source DB:  PubMed          Journal:  Arch Gynecol        ISSN: 0170-9925


  30 in total

1.  Müllerian adenosarcoma of the uterus: an ultrastructural study of four cases.

Authors:  A L Katzenstein; F B Askin; P S Feldman
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

2.  Müllerian adenosarcoma of the uterine cervix.

Authors:  A O Fayemi; M Ali; E V Braun
Journal:  Am J Obstet Gynecol       Date:  1978-03-15       Impact factor: 8.661

3.  Adenosarcoma of the uterus: ultrastructural observations.

Authors:  M C Bibro; V A LiVolsi; P E Schwartz
Journal:  Am J Clin Pathol       Date:  1979-01       Impact factor: 2.493

4.  Müllerian adenosarcoma of the uterus. A clinicopathologic analysis of ten cases of a distinctive type of müllerian mixed tumor.

Authors:  P B Clement; R E Scully
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

5.  Adenomyomatosis of endometrium and endocervix-a hamartoma.

Authors:  S G Silverberg
Journal:  Am J Clin Pathol       Date:  1975-08       Impact factor: 2.493

6.  Benign and low grade variants of mixed Müllerian tumour of the uterus.

Authors:  A G Ostör; D W Fortune
Journal:  Histopathology       Date:  1980-07       Impact factor: 5.087

7.  Spontaneous uterine neoplasms in the fat sand rat (Psammomys obesus).

Authors:  B Czernobilsky; H Ungar; J H Adler
Journal:  Lab Anim       Date:  1982-07       Impact factor: 2.471

8.  Carcinofibroma--a variant of the mixed Mullerian tumour. Case report.

Authors:  M Thompson; R Husemeyer
Journal:  Br J Obstet Gynaecol       Date:  1981-11

9.  Endometrial epithelial metaplasias: proliferations frequently misdiagnosed as adenocarcinoma. Report of 89 cases and proposed classification.

Authors:  M R Hendrickson; R L Kempson
Journal:  Am J Surg Pathol       Date:  1980-12       Impact factor: 6.394

10.  Müllerian adenosarcoma of the uterine body: a report of nine cases.

Authors:  H Fox; K R Harilal; A Youell
Journal:  Histopathology       Date:  1979-05       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.